Upcoming ESMO Congress will provide first look at data from Phase III Zelboraf study

1 September 2017

Roche (ROG: SIX) will present data from 18 approved and investigational programs at the European Society for Medical Oncology (ESMO) Congress, which kicks off in Madrid next Friday.

The Swiss drugmaker will provide Phase III data from its targeted medicines portfolio, including Zelboraf (vemurafenib) and Alecensa (alectinib), as well as updates from its immuno-oncology program.

The presentations will include the first batch of data from the Phase III BRIM8 study of Zelboraf for post-surgical treatment of BRAF V600 mutation-positive melanoma, which will be presented at the Presidential Symposium.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK